Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Current Assets (2020 - 2023)

Historic Current Assets for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $476.7 million.

  • Cullinan Therapeutics' Current Assets fell 1810.13% to $476.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $476.7 million, marking a year-over-year decrease of 1810.13%. This contributed to the annual value of $474.5 million for FY2022, which is 5998.97% up from last year.
  • Cullinan Therapeutics' Current Assets amounted to $476.7 million in Q3 2023, which was down 1810.13% from $498.2 million recorded in Q2 2023.
  • In the past 5 years, Cullinan Therapeutics' Current Assets registered a high of $622.8 million during Q2 2022, and its lowest value of $212.3 million during Q4 2020.
  • For the 4-year period, Cullinan Therapeutics' Current Assets averaged around $417.1 million, with its median value being $423.2 million (2021).
  • Within the past 5 years, the most significant YoY rise in Cullinan Therapeutics' Current Assets was 8081.3% (2022), while the steepest drop was 2794.16% (2022).
  • Quarter analysis of 4 years shows Cullinan Therapeutics' Current Assets stood at $212.3 million in 2020, then soared by 39.71% to $296.6 million in 2021, then surged by 59.99% to $474.5 million in 2022, then grew by 0.47% to $476.7 million in 2023.
  • Its Current Assets was $476.7 million in Q3 2023, compared to $498.2 million in Q2 2023 and $399.0 million in Q1 2023.